Trial Profile
A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Osilodrostat (Primary)
- Indications Pituitary ACTH hypersecretion
- Focus Pharmacokinetics
- Sponsors Recordati
- 07 Dec 2023 This trial has been completed in Slovenia, according to European Clinical Trials Database record.
- 09 Jun 2020 Planned End Date changed from 30 May 2023 to 29 Nov 2023.
- 09 Jun 2020 Planned primary completion date changed from 22 Aug 2022 to 21 Feb 2023.